NASDAQ · Financial Statements
Freeline Therapeutics Holdings plc (FRLN) Financial Statements
$6.49
NASDAQ: FRLN
Market Cap $28.28M
Overview Financials Dividend Freeline Therapeutics Holdings plc most recently reported annual revenue of $0, net profit of $-89.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2018 2019 2020 2021 2022 Revenue $0 $0 $0 $0 $0 Operating Profit $-41.0M $-64.0M $-102.0M $-142.0M $-98.0M Net Profit $-33.0M $-54.0M $-96.0M $-140.0M $-89.0M EPS $-78.65 $-127.39 $-102.09 $-58.98 $-22.52 Op Margin — — — — —
Balance Sheet (USD)
Metric 2018 2019 2020 2021 2022 Total Assets $32.0M $97.0M $269.0M $141.0M $87.0M Total Liabilities $9.0M $12.0M $19.0M $21.0M $34.0M Cash $16.0M $74.0M $230.0M $118.0M $47.0M Borrowings $0 $0 $0 $0 $6.0M
Cash Flow (USD)
Metric 2018 2019 2020 2021 2022 Operating Cash Flow $-26.0M $-52.0M $-95.0M $-108.0M $-78.0M Investing Cash Flow $-7.0M $-6.0M $-5.0M $-9.0M $-14.0M Financing Cash Flow $38.0M $115.0M $243.0M $-1.0M $28.0M Net Cash Flow $8.0M $58.0M $157.0M $-113.0M $-70.0M Free Cash Flow $-30.0M $-55.0M $-97.0M $-112.0M $-85.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.13 FCF Yield -301.37% Quick Ratio 1.61 Interest Coverage 0.00 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock